Division of Pulmonary and Critical Care
University of Michigan
University of Michigan COPD Quality Improvement Committee
Ann Arbor, Michigan
Director, UC Irvine Program in Medical
Education for the Latino Community
Associate Dean, School of Medicine
University of California, Irvine
The educational design of this activity addresses the needs of primary care and pulmonology clinicians who manage patients with chronic obstructive pulmonary disease (COPD).
Key updates to GOLD recommendations for the management of COPD include, but are not limited to, revisions to the older ABCD assessment tool, corresponding changes to the positioning of initial pharmacologic treatment options, and evidence supporting a reduction in mortality with pharmacologic therapy. These updates not only underscore the clinical relevance of exacerbations in COPD but provide enhanced guidance that can be easily be adopted into next day practice. In this Phone-a-Friend episode, Dr. Chuck Vega consults with Dr. MeiLan Han to discuss initial pharmacologic treatment options for a patient with newly diagnosed COPD.
After completing this activity, the participant should be better able to:
- Describe recent clinical trial data and guideline updates related to triple-combination inhaled therapies for COPD
- Tailor maintenance regimens for patients with COPD to reflect disease severity, treatable traits, exacerbation risks, comorbidities, and patient preferences
Physician Accreditation Statement
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationships
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
MeiLan K. Han, MD, MS: Consulting Fees: Aerogen, Altesa BioSciences, Inc., Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Chiesi USA Inc., Cipla Inc., DevPro Biopharma LLC., GSK plc, Integrity, Merck & Co., Inc., Mylan N.V., Novartis Pharmaceuticals Corporation, Polarean, Inc., Pulmonx Corporation, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Verona Pharma plc; Contracted Research: AstraZeneca, Biodesix, Inc., Boehringer Ingelheim International GmbH, Gala Therapeutics, Inc., Novartis Pharmaceuticals Corporation, Nuvaira Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc.; Ownership Interest (Stock Options): Altesa BioSciences, Inc., Meissa Vaccines, Inc.
Charles P. Vega, MD, FAAFP: Consulting Fees: Boehringer Ingelheim International GmbH, GSK plc
The planners and managers at Integritas Communications have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 100% on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Integritas Contact Information
For questions about this activity, please contact Integritas Communications at firstname.lastname@example.org.